Minneapolis-based life settlements specialist GWG Life claims it is the first insuretech company to apply “epigenetic technology” in a way that it says could transform life insurance underwriting (link below).
Saliva samples are being used to analyze the overall health and life expectancy of policy owners. The samples contain cells that can be analyzed for specific levels of methylation that occur in epigenetic biomarkers which are said to be predictive of an individual’s risk of all-cause mortality.
This would contribute to a more accurate estimate of the life expectancy of policyholders, a key factor for CWG’s secondary market business.
“The technology could significantly improve the life insurance underwriting process in terms of its accuracy, speed and cost. I can clearly envision the day when life insurance purchasers will no longer be subjected to traditional invasive underwriting practices.”
Will this – or perhaps marrying this and what they’re doing with big data analytics – make a big impact on the life insurance underwriting environment?
Insurance Forums | Advances in underwriting: Saliva samples now being used to analyze biomarkers of settlement prospects